The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

CIDP Companies across the globe are diligently working toward developing novel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment therapies with a considerable amount of success ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, Mechanism of Action, Route of Administration by DelveInsight ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 16, Bank of America Securities analyst Tazeen Ahmad maintained a bullish stance on Argenx SE (NASDAQ:ARGX), ...

ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of ...